Antioxidant activity of blueberry fruit is impaired by association with milk
“When blueberries and milk were ingested there was no increase in plasma antioxidant capacity. There was a reduction in the peak plasma concentrations of caffeic and ferulic acid (-49.7%, p<0.001, and -19.8%, p<0.05, respectively) as well as the overall absorption (AUC) of caffeic acid (p<0.001). The ingestion of blueberries in association with milk, thus, impairs the in vivo antioxidant properties of blueberries and reduces the absorption of caffeic acid.”
Accessible overview:
My own view: maybe, but why take the chance? YMMV.
The provided transcript outlines dietary interventions targeting visceral adiposity and non-alcoholic fatty liver disease (NAFLD, recently updated in clinical literature to metabolic dysfunction-associated steatotic liver disease, MASLD). The central thesis posits that hepatic steatosis can be rapidly reversed through specific macronutrient and phytochemical modulations, independently of total body weight loss. The speaker highlights dietary polyphenols, increased protein intake, unsaturated fatty acids, and resistant starch (RS2) as primary effectors for hepatic fat oxidation and the suppression of de novo lipogenesis.
While the narrative is largely grounded in established clinical trials—specifically referencing the DIRECT PLUS trial for the Green Mediterranean diet and the DiRECT trial for extreme hypocaloric interventions—it occasionally conflates acute metabolic ward study results with sustainable outpatient protocols. The introductory assertion that visceral fat can be reversed “in weeks with little to no effort” is a hyperbolic marketing hook that contradicts the high-compliance nature of the cited clinical interventions, such as consuming 100 grams of duckweed daily or adhering to a 600-calorie liquid diet.
From a longevity and biotech perspective, the transcript successfully identifies high-yield metabolic pathways. The emphasis on polyphenol-induced metabolic shifts and the microbiome-mediated effects of resistant starch align with current anti-aging research focusing on metabolic flexibility and insulin sensitivity. Furthermore, the explicit warning regarding saturated fats inducing steatosis more aggressively than simple sugars accurately reflects recent human lipidomics data, challenging prevailing low-carbohydrate orthodoxies.
However, the translational gap remains a practical concern. While specific protocols like the RS2 supplementation demonstrate profound clinical efficacy (a 50% reduction in liver fat), commercial availability and long-term human adherence outside trial settings are highly variable. Ultimately, the interventions discussed present a viable, evidence-based roadmap for metabolic rehabilitation, provided the initial hyperbole is discarded and the protocols are integrated into a rigorous, compliance-driven framework. The core utility lies in leveraging specific compounds—catechins, curcumin, and short-chain fatty acid precursors—to modulate the liver’s energy partitioning and inflammatory cascades, thereby expanding healthspan and mitigating the risk of metabolic syndrome-associated morbidities.
II. Insight Bullets
Visceral adiposity, specifically intrahepatic lipid accumulation, is a primary driver of metabolic syndrome, cardiovascular disease, and type 2 diabetes.
The Green Mediterranean diet, augmented with high polyphenol intake, significantly outperforms the standard Mediterranean diet in reducing hepatic steatosis.
Daily consumption of 100 grams of Mankai duckweed and 3-4 cups of green tea doubles liver fat reduction over 18 months compared to standard dietary interventions.
Dietary polyphenols effectively reduce liver fat independently of caloric restriction or significant total body weight loss.
Curcumin supplementation, when co-administered with piperine (black pepper) for bioavailability, demonstrates clinical efficacy in reducing liver fat within an 8-week timeframe.
Matcha provides a higher concentration of catechins than standard green tea due to the ingestion of the entire pulverized leaf.
Shifting dietary protein intake from 10% to 30% of total calories can reduce liver fat by up to 42% in 21 days.
High protein intake suppresses hepatic lipogenesis while simultaneously upregulating fat oxidation pathways.
Extreme hypocaloric interventions (600 kcal/day liquid shakes) can deplete hepatic lipid stores by 30% in just 7 days.
The 600 kcal/day protocol normalizes fasting blood glucose in type 2 diabetics within one week, highlighting the rapid plasticity of hepatic insulin sensitivity.
Saturated fatty acids (butter, palm oil, processed meats) are more steatogenic than simple carbohydrates, driving rapid liver fat accumulation.
Purified, concentrated fructose in ultra-processed foods heavily promotes hepatic de novo lipogenesis.
Whole fruit consumption does not induce fatty liver; the intrinsic fiber matrix slows digestion and alters the metabolic handling of endogenous fructose.
Commercial yogurts and packaged beverages frequently harbor hidden refined sugars, negating their marketed health benefits.
Unsweetened Greek yogurt paired with allulose or stevia provides a metabolically safe alternative for protein and satiety.
Choline, highly concentrated in whole eggs, is a requisite micronutrient for hepatic lipid export (VLDL synthesis).
Resistant starch type 2 (RS2) bypasses enzymatic digestion in the small intestine, acting as a prebiotic substrate in the colon.
Daily supplementation of 40 grams of RS2 derived from high-amylose corn can reduce liver fat by 50% over four months.
The RS2 protocol achieved primary endpoints without requiring concurrent modifications to caloric intake or physical activity.
III. Adversarial Claims & Evidence Table
Specific Claim
What they cited
Verified status + PubMed/DOI Link
Evidence Grade
Verdict
Green Med diet + duckweed + green tea doubles liver fat loss vs. Med diet.
Macronutrient Repartitioning: Increase dietary protein to 25-30% of total caloric intake. This suppresses endogenous fat production and increases thermogenesis and satiety.
Polyphenol Loading: Integrate 3 to 4 cups of green tea or 1 to 2 servings of high-grade matcha daily. Incorporate polyphenol-dense foods such as pecans, artichokes, and dark chocolate (>85% cacao).
Experimental Tier (Level B/C Evidence with High Safety Margins)
Resistant Starch Supplementation: Incorporate 40 grams of Resistant Starch Type 2 (RS2) daily. Due to limited commercial availability of high-amylose corn RS2, viable alternatives include raw potato starch or green banana flour mixed into cold water (heating destroys the resistant starch matrix).
Targeted Phytonutrients: Supplement with curcumin (500-1000 mg/day) formulated with piperine or utilizing liposomal delivery systems to overcome poor oral bioavailability.
Red Flag Zone (Safety Warnings)
Severe Caloric Restriction (600 kcal/day): While highly effective for rapid hepatic lipid clearance, this protocol (DiRECT) carries high risks of lean mass catabolism, gallstone formation, and micronutrient deficiencies. It should only be executed under continuous medical supervision.
Fructose & Saturated Fat Co-ingestion: The combination of refined fructose (sweetened beverages) and saturated fats (processed meats, pastries) is the most potent driver of hepatic lipotoxicity and must be entirely eliminated from the diet.
V. Technical Mechanism Breakdown
Hepatic De Novo Lipogenesis (DNL) & Fructose Metabolism: Unlike glucose, which is strictly regulated by phosphofructokinase, fructose metabolism in the liver bypasses this rate-limiting step. It provides an unregulated supply of carbon substrates (acetyl-CoA) that drive DNL. Fructose phosphorylation also aggressively depletes hepatic ATP, generating uric acid, which induces mitochondrial oxidative stress and exacerbates insulin resistance.
Lipotoxicity of Saturated Fats: Saturated fatty acids (e.g., palmitate) directly induce endoplasmic reticulum (ER) stress and promote the synthesis of toxic lipid intermediates like ceramides and diacylglycerols (DAGs). These intermediates inhibit insulin signaling pathways (specifically interfering with IRS-1 and Akt phosphorylation), rapidly driving hepatic insulin resistance and steatosis.
Polyphenol Action via AMPK: Polyphenols (such as EGCG from matcha) act as xenohormetic stressors, upregulating AMP-activated protein kinase (AMPK). AMPK activation switches the hepatic metabolic profile from anabolic to catabolic by inhibiting acetyl-CoA carboxylase (ACC), thereby decreasing DNL and upregulating carnitine palmitoyltransferase 1 (CPT-1), which accelerates mitochondrial beta-oxidation of fatty acids.
Microbiome & Resistant Starch (RS2): RS2 evades human amylase and reaches the colon intact, where it undergoes bacterial fermentation. This yields short-chain fatty acids (SCFAs), primarily butyrate, propionate, and acetate. SCFAs enter the portal circulation, activating hepatic AMP-activated protein kinase (AMPK), modulating bile acid synthesis, and promoting the secretion of GLP-1 from intestinal L-cells. Furthermore, RS2 fermentation lowers colonic pH, inhibiting the growth of pathogenic bacteria and reducing the translocation of lipopolysaccharides (LPS) to the liver, thereby dampening hepatic innate immune activation (Kupffer cell inflammation).
The CRONITE’s are going to know they were here first, with their lean and fit, perhaps robust physique, once everyone has oral retatrutide equivalent + muscle myostatin inhibitor.
Just had a DEXA scan this morning, and things are moving in the right direction. I exercise about 4 or 5 times a week, alternating resistance training and cardio. I’m going to try microdosing a GLP1 to see if we can speed the process up a bit on that visceral fat reduction. Will report on my results…
How You Gain Visceral Fat & How to Lose it | Dr. Rhonda Patrick & Dr. Andrew Huberman
Executive Summary
This report evaluates the metabolic and systemic implications of visceral adipose tissue (VAT) accumulation as presented by Dr. Rhonda Patrick and Dr. Andrew Huberman. The primary thesis identifies VAT not merely as a storage depot, but as an active endocrine and pro-inflammatory organ that disrupts systemic homeostasis through the unregulated release of free fatty acids (FFAs) and cytokines.
The analysis underscores a critical biological distinction: while subcutaneous fat is responsive to insulin-mediated lipolysis inhibition, VAT exhibits a “lipolytic escape” mechanism. This resistance to insulin allows VAT to continuously release FFAs into the portal circulation, directly antagonizing hepatic insulin receptors and precipitating non-alcoholic fatty liver disease (NAFLD) and peripheral insulin resistance.
Crucially, recent clinical data (Nature Metabolism, 2025) supports the claim that brain insulin resistance can manifest in as little as five days of high-calorie, ultra-processed feeding, even in the absence of measurable weight gain. This “neurometabolic” dysfunction impairs satiety signaling and creates a positive feedback loop for further visceral deposition. Furthermore, sleep restriction—specifically a 4-hour nightly window—has been shown to increase VAT by 11% in just two weeks, indicating that sleep hygiene is a primary metabolic regulator alongside caloric balance.
While the “proxy” thresholds of 35 inches (women) and 40 inches (men) for waist circumference remain clinically valid, the report highlights the “TOFI” (Thin Outside, Fat Inside) phenomenon, where individuals with a normal BMI harbor dangerous VAT levels. Strategic interventions including High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT) are evaluated as equally effective for VAT reduction, though HIIT offers superior improvements in glycemic control and VO2 max. This analysis concludes that visceral fat management must prioritize metabolic flexibility and circadian regulation over simple weight-centric metrics.
II. Insight Bullets
VAT as Endocrine Organ: Visceral fat actively secretes hormones and pro-inflammatory cytokines, distinguishing it from inert subcutaneous fat.
Portal Vein Danger: VAT drains directly into the portal vein, “mainlining” free fatty acids to the liver and triggering insulin resistance.
Insulin Response Failure: Unlike subcutaneous fat, VAT does not shut down lipolysis effectively in response to insulin spikes.
Mortality Risk: High VAT levels are associated with a 2x increase in early death risk and a significantly higher (44-100%) risk of obesity-related cancers.
Neurometabolic Speed: Brain insulin resistance can occur within 5 days of a high-fat, high-sugar diet before any weight gain is detected.
The TOFI Risk: “Skinny fat” individuals can harbor high VAT, making BMI an insufficient metric for metabolic health.
Sleep-Driven Accumulation: Shortened sleep (4 hours) increases VAT by 11% in healthy individuals within 14 days (Covassin et al., 2022).
Menopause Shift: Estrogen loss in women over 50 shifts fat storage from subcutaneous to visceral compartments.
Waist Proxy: 35 inches (women) and 40 inches (men) are robust proxies for VAT-related health risk (AARP/Manson, 2026).
Lethargy Cycle: VAT-induced inflammation acts as an “energy sink,” leading to chronic fatigue and energy crashes.
Reactive Hyperinsulinemia: Insulin resistance leads to overcompensation of insulin, causing blood glucose crashes and subsequent cravings.
Cortisol Link: Chronically elevated cortisol levels preferentially direct energy storage to visceral depots.
HIIT Efficacy: HIIT is highly effective for VAT loss and superior to aerobic exercise for reducing fasting glucose (Kramer et al., 2023).
Satiety Impairment: Brain insulin resistance disables the “stop eating” signal in the hypothalamus.
Catch-up Sleep Failure: Resuming normal sleep after restriction does not immediately reverse VAT gains.
Dietary Composition: High saturated fat and refined sugar are the primary drivers of rapid VAT and liver fat gain.
Liver Storage: Because VAT is adjacent to the liver, excess FFAs force hepatic storage, leading to NAFLD.
Cancer Mechanism: Chronic inflammation from VAT creates a tumor-promoting environment through DNA damage and hormone disruption.
Intermittent Fasting (IF): IF is effective for improving insulin sensitivity but long-term fat loss is comparable to continuous caloric restriction.
DEXA Gold Standard: DEXA scans remain the only reliable direct measure for quantifying VAT vs. subcutaneous fat.
III. Adversarial Claims & Evidence Table
Claim from Video
Speaker’s Evidence
Scientific Reality (Current Data)
Evidence Grade
Verdict
Brain insulin resistance in 5 days.
“Recent Newsletter” / Study citing 5 days overfeeding.
PubMed (2026) highest VAT quartile associated with 1.7x all-cause and 2.9x cardiometabolic mortality.
A
Strong Support
Visceral fat resists insulin lipolysis.
Mechanism of portal circulation.
Well-established; VAT has higher β-adrenoceptor density and lower insulin receptor sensitivity than SAT.
C
Plausible
HIIT “powerfully” loses visceral fat.
Anecdotal + Exercise science.
Kramer et al. (2023) Meta-analysis: HIIT is effective but not superior to MICT for fat mass, though better for glucose.
A
Plausible
IV. Actionable Protocol (Prioritized)
High Confidence Tier (Level A/B Evidence)
Sleep Minimum: Maintain >7 hours of sleep to prevent the “visceral redirection” of fat. 4-hour nights are a high-risk trigger for rapid VAT accumulation.
Waist Monitoring: Track waist circumference at the navel. Targets: Men < 40 in, Women < 35 in. For Asian populations, thresholds are lower (Men < 35.5, Women < 31.5).
Caloric Deficit + Aerobic/HIIT: Combine moderate-intensity cardio (MICT) for sustainability with 1-2 HIIT sessions weekly for maximal glycemic benefit.
Experimental Tier (Level C/D Evidence)
Intermittent Fasting (Time-Restricted Eating): Use an 8-10 hour feeding window to improve insulin sensitivity, though overall caloric intake remains the primary driver.
Ultra-Processed Elimination: Aggressively remove HFHS (High Fat, High Sugar) snacks to prevent rapid brain insulin desensitization.
Red Flag Zone (Safety Data Absent)
“Skinny Fat” Reassurance: Do not rely on a low scale weight. If waist circumference is increasing while weight is stable, metabolic dysfunction is likely present.
Chronic Cortisol Management: While cortisol is a known driver, specific “anti-cortisol” supplements lack robust Level A/B evidence for VAT reduction.
V. Technical Mechanism Breakdown
The transition from healthy energy storage to visceral pathology centers on Lipolytic Dysregulation:
Subcutaneous Satiation: Subcutaneous adipose tissue (SAT) acts as a safe metabolic sink. When SAT becomes “full” or dysfunctional (due to inflammation or low estrogen), excess energy is shunted to the visceral depot.
Insulin Resistance Pathway:
In SAT: Insulin binds to receptors, inhibiting Hormone-Sensitive Lipase (HSL) and stopping the release of FFAs.
In VAT: Insulin signaling is weak. HSL remains active, continuously breaking down triglycerides into FFAs.
Portal Mainlining: These FFAs enter the portal vein and travel directly to the liver.
Hepatic Impact: The liver is flooded with FFAs, causing Intrahepatic Lipid Accumulation. This induces hepatic insulin resistance, leading to increased gluconeogenesis (high fasting blood sugar) and VLDL secretion.
Neurological Feedback: High circulating FFAs and cytokines (TNF-α, IL-6) cross the blood-brain barrier, inducing hypothalamic insulin resistance. This blunts the satiety response to meals, driving hyperphagia (overeating) and further fat deposition.
Interesting paper - this alternative paper suggests dairy reduces oxidization of the anthocyanins and so improves bioavailability
“Recent research suggests that while milk might slow down absorption in the stomach, it may actually protect anthocyanins from degrading in the harsh environment of the gut, potentially leading to better absorption later in the digestive tract”
Source: Wiley Online Library https://share.google/5QdgLOguRsh4nQiHZ
But I doubt science has a conclusive answer. Gemini came down on the side of there being a net benefit from combining blueberries and kefir/yoghurt. Enough encouragement for me to keep going!
https://share.google/aimode/MubxTSzQiW6ZNFyy2
The Verdict: The net benefit of eating them together (probiotics + fiber + vitamins + slightly slower-absorbing antioxidants) outweighs the “disbenefit” of the minor antioxidant binding.
But i suspect this won’t be our most critical decision for longevity either way!
Do you recall which machine was used in its test. My local university performance lab offers the test for $66. I saw this note when I went up to pay for a test.
We have recently transitioned from a GE DXA system to a Hologic DXA system. It is important to understand that measurements such as bone mineral content (BMC), bone mineral density (BMD), and lean mass can differ between these two systems. Research consistently shows that GE DXA systems tend to report higher values for these measures compared to Hologic systems, even when scans are performed on the same person (Park et al., 2021; Shepherd et al., 2012; Vendrami et al.,2024). These differences are due to variations in hardware, calibration, and proprietary analysis algorithms, and there is currently no universal reference standard that allows direct comparison of results between the two manufacturers (Crabtree et al., 2017; Shepherd et al., 2012; Vendrami et al., 2024).
I’ll post more on this later but the lack of concordance between the two machines is as insane as the contrived explanations for the problem. Example: a theoretically true bone mass of 4% could report 3.6-3.4% on one machine, triggering concern and restrictions on weight bearing exercises, while the other machine – run the same day – might report 4.4-4.6%, providing a green light for weight lifting with possible fractures attendant.
